A new wave of experimental weight-loss drugs is drawing serious attention from researchers and patients frustrated with the limitations of current GLP-1 medications.
Drugs like Zepbound and Wegovy have transformed obesity treatment, but persistent side effects such as severe nausea and vomiting remain a significant barrier for many patients.
Scientists are now developing alternatives that target different hormonal pathways in the body, potentially delivering better results with fewer of the gastrointestinal drawbacks that trouble so many users.
One experimental drug generating strong interest is cagrilintide, which works by targeting amylin receptors rather than relying solely on GLP-1 receptor activation.
GLP-1 receptors in the brain’s area postrema “drive most of your nausea,” while amylin receptors follow a slightly different pathway associated with less nausea.
This distinction is significant because it could allow patients to achieve meaningful weight loss without enduring the debilitating stomach side effects that cause many to abandon current treatments.
Another experimental candidate, retatrutide, functions as a weekly injection similar in format to Wegovy and Zepbound, but it targets three separate hormonal pathways simultaneously.
Retatrutide hits GLP-1, GIP, and a third hormone called glucagon, giving it a broader mechanism of action than any weight-loss drug currently approved for widespread use.
In a Phase 3 trial, patients taking the highest dose of retatrutide lost nearly 29% of their body weight over approximately 16 months, surpassing results seen with any GLP-1 drug currently on the market.
Eli Lilly (LLY) is also developing orforglipron, an oral GLP-1 pill targeting both weight loss and type 2 diabetes, offering a daily tablet option for patients who prefer to avoid injections.
For patients who find weekly injections manageable but struggle with daily pill routines, orforglipron presents a potentially more demanding schedule than injectable alternatives currently on the market.
The broader pipeline of next-generation obesity drugs signals that competition in this space is intensifying rapidly, with pharmaceutical companies racing to capture a market already worth hundreds of billions of dollars.
Novo Nordisk (NVO), the maker of Wegovy, and Eli Lilly (LLY), the maker of Zepbound, currently dominate the GLP-1 landscape but face growing pressure from emerging competitors developing these novel compounds.
Patients and physicians alike are watching the progress of these experimental therapies closely, hoping that improved tolerability and stronger efficacy will expand access to effective obesity treatment for a far wider population.
